- Predicting enrollment trends to ensure uninterrupted clinical trial supply
- Using data-driven forecasting to support agile decision-making
- Managing uncertainty across global, multi-site studies
- Best practices for responding to faster-than-expected recruitment and changing demand
- 预测入组趋势，确保临床试验供应不中断。
- 使用数据驱动的预测支持快速决策。
- 管理全球多中心研究中的不确定性。
- 应对超预期快速招募和需求变化的最佳实践。
Moderator: Daniel Gao, President, ISPE Supply Chain
Securing the right comparator drug is often the most critical yet daunting hurdle in planning a registration trial in China. Unlike other supplies, a comparator is not merely a commodity; it is a regulatory benchmark, a clinical necessity, and a potential bottleneck that can derail timelines and compromise data integrity.
- Strategies to ensure unbroken supply continuity.
- Risk mitigation plans for sourcing uncertainties.
- Practical insights from global pharmaceutical business.
在筹备中国注册临床试验的过程中，获取正确的对照药往往是最关键但也最棘手的难题。与其他临床供应品不同，对照药不仅仅是一种物资，它更是监管的基准、临床的必需品，也是一个极易导致项目延期并损害数据完整性的潜在瓶颈。
- 保障供应链持续不中断的应对策略
- 针对采购不确定性的风险缓解计划
- 来自全球制药企业的实用洞察
Patient enrollment remains one of the most critical bottlenecks in global drug development, often delaying timelines, increasing costs, and limiting patient access to innovative therapies. Against this backdrop, China has emerged not merely as a region of vast patient numbers, but as a laboratory for systemic innovation in clinical trial execution. 患者入组仍是全球药物开发中最关键的瓶颈之一，常常导致时间线延误、成本上涨，而且还会限制患者获得创新疗法的机会。在这一背景下，中国利用其庞大的患者数量而，不断发展临床试验执行中的体系创新。
- How China Building Beyond “Population Advantage”
- How to Leverage AI and Digital Platforms in Patient Matching
- The Power of Hospital Alliances and Regional Clinical Hubs
- Aligning Patient Recruitment, Clinical Supply Strategy And Site Readiness To Reduce Delays
- How to Adapt China’s Model for International Multi-Center Trials
- 中国不仅是“人口优势”
- 如何利用 AI 与数字平台进行患者匹配
- 医院联盟与区域临床中心的发展
- 患者招募、临床供应策略的动态调整
- 如何将中国模式应用于MRCT
|
Moderator: Sarah Nightingale, APAC Principal Consultant, GlobalData
